eXoZymes Inc. Common Stock (EXOZ)

FairStock Score: 13/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I approach eXoZymes as a Graham-style net-asset and earnings skeptic. The company is a 32-employee development-stage biotech working on enzyme modules and cell-free biosolutions, but the numbers show no commercial engine yet. In fiscal FY2023, the year ended 2023-12-31, it reported revenue of $70,069 and a net loss of $2.0M, or diluted EPS of $-0.33. By fiscal FY2024, the year ended 2024-12-31, net loss widened to $5.9M and diluted EPS to $-0.89; in fiscal FY2025, the year ended 2025-12-31, net loss reached $9.2M and diluted EPS $-1.09. Recent quarters are still bleeding: in fiscal Q1 2026, the quarter ended 2026-03-31, net loss was $2.4M and diluted EPS $-0.28; in fiscal Q2 2026, the quarter ended 2026-06-30, net loss was $2.9M and diluted EPS $-0.33. No revenue is reported in those filings. Trailing free cash flow is -$7.1M, a FairStock-calculated FCF yield of -16.8%. FairStock calculations also show ROE of -187.16%, ROCE of -74.74%, P/B of 11.77 at the 2026-10-13 close of $4.59, and a Piotroski F-Score of 2/9. The Altman Z-Score of 1.97 suggests financial stress, though D/E is 0.30. With a $42.6M market cap, FairStock score 13/100, and no Lynch category because of losses in each of the last three years, I see no demonstrated moat, no earnings, and a price that already assumes a successful future. Growth is negative in the sense that losses are escalating, not revenue. I would want proof of commercial traction and a path to self-funding before calling this a value opportunity.

In plain English: eXoZymes is a small development-stage biotechnology company that works on enzyme-based manufacturing tools. It has not reported meaningful revenue and is losing money, with losses growing. At its 2026-10-13 closing price of $4.59, the stock looks expensive compared with its weak financial results.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer